Cargando…

IL-23 Blockade in Anti-TNF Refractory IBD: From Mechanisms to Clinical Reality

Increasing insights into the immunopathogenesis of inflammatory bowel diseases [IBD] have led to the advent of targeted therapies that inhibit crucial mediators of the inflammatory process, thereby widening our available therapeutic armamentarium. Anti-tumour necrosis factor [anti-TNF] agents are st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Atreya, Raja, Neurath, Markus F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Supplement Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097672/ https://www.ncbi.nlm.nih.gov/pubmed/35553662 http://dx.doi.org/10.1093/ecco-jcc/jjac007

Ejemplares similares

Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF?
por: Atreya, Raja, et al.
Publicado: (2020)

Functional Molecular Network Analysis Enables Prediction of Response to Vedolizumab Therapy in Anti-TNF Refractory IBD Patients
por: Breidert, Matthias, et al.
Publicado: (2020)

Role of the IL23/IL17 Pathway in Crohn’s Disease
por: Schmitt, Heike, et al.
Publicado: (2021)

IL-23 Monoclonal Antibodies for IBD: So Many, So Different?
por: McDonald, Benjamin D, et al.
Publicado: (2022)

What Can IBD Specialists Learn from IL-23 Trials in Dermatology?
por: Valenti, Mario, et al.
Publicado: (2022)

All are Equal, Some are More Equal: Targeting IL 12 and 23 in IBD – A Clinical Perspective
por: Jefremow, André, et al.
Publicado: (2020)

Oligonucleotides—A Novel Promising Therapeutic Option for IBD
por: Scarozza, Patrizio, et al.
Publicado: (2019)

Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study
por: Mühl, Laura, et al.
Publicado: (2021)

Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn’s disease
por: Schmitt, Heike, et al.
Publicado: (2019)

Mild COVID-19 Symptoms in an Infliximab-Treated Ulcerative Colitis Patient: Can Ongoing Anti-TNF Therapy Protect against the Viral Hyperinflammatory Response and Avoid Aggravated Outcomes?
por: Abdullah, Abdullah, et al.
Publicado: (2020)

Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases
por: Billmeier, Ulrike, et al.
Publicado: (2016)

COVID-19 and immunomodulation in IBD
por: Neurath, Markus F
Publicado: (2020)

Case Report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma
por: Zundler, Sebastian, et al.
Publicado: (2023)

Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling
por: Koelink, Pim J, et al.
Publicado: (2020)

IL-23 and axial disease: do they come together?
por: Mease, Philip, et al.
Publicado: (2021)

IL-23 orchestrating immune cell activation in arthritis
por: Najm, Aurélie, et al.
Publicado: (2021)

Blockade of IL-23: What is in the Pipeline?
por: Parigi, Tommaso Lorenzo, et al.
Publicado: (2022)

The Impact of Inflammatory Bowel Disease in Canada 2018: IBD in Seniors
por: Nguyen, Geoffrey C, et al.
Publicado: (2019)

The 2023 Impact of Inflammatory Bowel Disease in Canada: Epidemiology of IBD
por: Coward, Stephanie, et al.
Publicado: (2023)

The 2023 Impact of Inflammatory Bowel Disease in Canada: Cancer and IBD
por: Murthy, Sanjay K, et al.
Publicado: (2023)

Deciphering Novel Mechanistic and Pharmacokinetic Effects of Tofacitinib in Intestinal Inflammation: Expect the Unexpected
por: Atreya, Raja, et al.
Publicado: (2021)

The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD
por: Carroll, Matthew W, et al.
Publicado: (2019)

The 2023 Impact of Inflammatory Bowel Disease in Canada: COVID-19 and IBD
por: Kaplan, Gilaad G, et al.
Publicado: (2023)

Novel Small Molecules in IBD: Current State and Future Perspectives
por: Jefremow, André, et al.
Publicado: (2023)

The Impact of Inflammatory Bowel Disease in Canada 2018: Indirect Costs of IBD Care
por: Kuenzig, M Ellen, et al.
Publicado: (2019)

The Impact of Inflammatory Bowel Disease in Canada 2018: IBD Research Landscape in Canada
por: Rose, Keeley L, et al.
Publicado: (2019)

The Impact of Inflammatory Bowel Disease in Canada 2018: Extra-intestinal Diseases in IBD
por: Bernstein, Charles N, et al.
Publicado: (2019)

The 2023 Impact of Inflammatory Bowel Disease in Canada: Special Populations—IBD in Seniors
por: Shaffer, Seth R, et al.
Publicado: (2023)

Crossing the boundaries: IL-23 and its role in linking inflammation of the skin, gut and joints
por: Łukasik, Zuzanna, et al.
Publicado: (2021)

The 2023 Impact of Inflammatory Bowel Disease in Canada: Special Populations—Children and Adolescents with IBD
por: El-Matary, Wael, et al.
Publicado: (2023)

Clinical importance of IL-22 cascade in IBD
por: Mizoguchi, Atsushi, et al.
Publicado: (2017)

Endoscopic Therapy in Inflammatory Bowel Diseases
por: Neumann, Helmut, et al.
Publicado: (2015)

IL23 Promotes Antimicrobial Pathways in Human Macrophages, Which Are Reduced With the IBD-Protective IL23R R381Q Variant
por: Sun, Rui, et al.
Publicado: (2020)

Evolution of IL-23 Blockade in Inflammatory Bowel Disease
por: Danese, Silvio, et al.
Publicado: (2022)

Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Seniors With IBD
por: Bernstein, Charles N, et al.
Publicado: (2021)

Changes in myoblast responsiveness to TNFα and IL-6 contribute to decreased skeletal muscle mass in intrauterine growth restricted fetal sheep
por: Posont, Robert J, et al.
Publicado: (2018)

Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy
por: Schierova, Dagmar, et al.
Publicado: (2021)

Personalised Medicine with IL-23 Blockers: Myth or Reality?
por: Gottlieb, Zoë S, et al.
Publicado: (2021)

Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases
por: Rath, Timo, et al.
Publicado: (2018)

Editorial: Personalizing Treatment in IBD: Hype or Reality in 2020?
por: Gomollón, Fernando, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4femtrmtqthsqkbp9o5827v7pk